Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEP NASDAQ:CRVO NASDAQ:HOWL NASDAQ:LIXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$15.38+2.5%$14.25$2.31▼$19.19$74.13M-0.4960,591 shs26,301 shsCRVOCervoMed$7.08-6.8%$8.90$1.80▼$16.94$65.49M-0.84109,431 shs124,824 shsHOWLWerewolf Therapeutics$1.60-4.2%$1.56$0.60▼$4.18$73.17M0.761.70 million shs555,555 shsLIXTLixte Biotechnology$4.50+3.2%$4.62$0.64▼$6.26$25.65M0.48152,053 shs107,681 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics0.00%-2.04%+10.81%+43.74%+267.24%CRVOCervoMed0.00%-13.13%-9.11%-16.01%-50.49%HOWLWerewolf Therapeutics0.00%-1.84%+7.38%+14.29%-21.95%LIXTLixte Biotechnology0.00%-5.66%-17.43%+14.80%+138.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$15.38+2.5%$14.25$2.31▼$19.19$74.13M-0.4960,591 shs26,301 shsCRVOCervoMed$7.08-6.8%$8.90$1.80▼$16.94$65.49M-0.84109,431 shs124,824 shsHOWLWerewolf Therapeutics$1.60-4.2%$1.56$0.60▼$4.18$73.17M0.761.70 million shs555,555 shsLIXTLixte Biotechnology$4.50+3.2%$4.62$0.64▼$6.26$25.65M0.48152,053 shs107,681 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics0.00%-2.04%+10.81%+43.74%+267.24%CRVOCervoMed0.00%-13.13%-9.11%-16.01%-50.49%HOWLWerewolf Therapeutics0.00%-1.84%+7.38%+14.29%-21.95%LIXTLixte Biotechnology0.00%-5.66%-17.43%+14.80%+138.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 1.00SellN/AN/ACRVOCervoMed 2.45Hold$19.86180.47% UpsideHOWLWerewolf Therapeutics 2.86Moderate Buy$8.00400.00% UpsideLIXTLixte Biotechnology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest LIXT, CRVO, HOWL, and COEP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025CRVOCervoMedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$20.0010/16/2025HOWLWerewolf TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/13/2025CRVOCervoMedZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/8/2025COEPCoeptis TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CRVOCervoMedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025HOWLWerewolf TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LIXTLixte BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025COEPCoeptis TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CRVOCervoMedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025HOWLWerewolf TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LIXTLixte BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis TherapeuticsN/AN/AN/AN/A$1.61 per shareN/ACRVOCervoMed$9.74M6.72N/AN/A$4.50 per share1.57HOWLWerewolf Therapeutics$1.88M38.92N/AN/A$1.65 per share0.97LIXTLixte BiotechnologyN/AN/AN/AN/A($1.19) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-201.73%-108.46%N/ACRVOCervoMed-$16.29M-$2.61N/AN/AN/A-290.72%-59.15%-53.64%11/11/2025 (Estimated)HOWLWerewolf Therapeutics-$70.51M-$1.64N/AN/AN/AN/A-111.87%-62.68%11/6/2025 (Estimated)LIXTLixte Biotechnology-$3.59M-$1.29N/A∞N/AN/AN/A-222.90%11/11/2025 (Estimated)Latest LIXT, CRVO, HOWL, and COEP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CRVOCervoMed-$0.68N/AN/AN/A$1.43 millionN/A11/6/2025Q3 2025HOWLWerewolf Therapeutics-$0.39N/AN/AN/AN/AN/A8/14/2025Q2 2025COEPCoeptis TherapeuticsN/A-$1.17N/A-$1.17N/A$0.20 million8/14/2025Q2 2025HOWLWerewolf Therapeutics-$0.50-$0.40+$0.10-$0.40$1.50 millionN/A8/8/2025Q2 2025CRVOCervoMed-$0.57-$0.70-$0.13-$0.70$1.45 million$1.76 million8/7/2025Q2 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.020.830.83CRVOCervoMedN/A8.208.20HOWLWerewolf Therapeutics0.605.305.30LIXTLixte BiotechnologyN/A1.841.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%CRVOCervoMed25.15%HOWLWerewolf Therapeutics64.84%LIXTLixte Biotechnology5.10%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%CRVOCervoMed35.40%HOWLWerewolf Therapeutics23.60%LIXTLixte Biotechnology14.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics24.82 million3.65 millionNot OptionableCRVOCervoMed49.25 million5.98 millionNot OptionableHOWLWerewolf Therapeutics4045.73 million34.94 millionOptionableLIXTLixte Biotechnology45.70 million4.86 millionNot OptionableLIXT, CRVO, HOWL, and COEP HeadlinesRecent News About These CompaniesLIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition PlansOctober 16, 2025 | globenewswire.comLixte Biotechnology Holdings, Inc.: LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own FutureSeptember 16, 2025 | finanznachrichten.deLixte Biotechnology Holdings, Inc.: LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury StrategySeptember 16, 2025 | finanznachrichten.deLIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)September 16, 2025 | accessnewswire.comALIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)September 15, 2025 | accessnewswire.comALixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum for $2.6MSeptember 10, 2025 | msn.comLIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential AcquisitionsSeptember 10, 2025 | globenewswire.com24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A InhibitorSeptember 5, 2025 | newsfilecorp.comNLixte Biotechnology appoints two new board members, Stazzone as CFOSeptember 3, 2025 | msn.comLIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial OfficerSeptember 3, 2025 | globenewswire.com24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer TherapyAugust 27, 2025 | globenewswire.com24/7 Market News: LIXTE Targets Large, Unmet Oncology MarketsAugust 25, 2025 | globenewswire.com24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100August 19, 2025 | globenewswire.comLixte Biotechnology Raises $6.5M, Appoints New ManagementAugust 19, 2025 | msn.comLixte Biotechnology provides update on recent corporate activitiesAugust 18, 2025 | msn.comLIXTE Biotechnology Holdings Provides Corporate UpdateAugust 18, 2025 | globenewswire.com24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025August 14, 2025 | globenewswire.com24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025August 14, 2025 | finance.yahoo.com24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025August 14, 2025 | globenewswire.com24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury StrategyAugust 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIXT, CRVO, HOWL, and COEP Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$15.38 +0.38 (+2.53%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$15.30 -0.08 (-0.49%) As of 10/17/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.CervoMed NASDAQ:CRVO$7.08 -0.52 (-6.84%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$7.52 +0.44 (+6.21%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Werewolf Therapeutics NASDAQ:HOWL$1.60 -0.07 (-4.19%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.60 -0.01 (-0.31%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Lixte Biotechnology NASDAQ:LIXT$4.50 +0.14 (+3.21%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.44 -0.06 (-1.31%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
